{"id":72220,"date":"2026-08-05T00:46:15","date_gmt":"2026-08-04T22:46:15","guid":{"rendered":"https:\/\/inmuno.es\/index.php\/2026\/08\/05\/meditope-enabled-chimeric-antigen-receptors-facilitate-plug-and-play-control-of-t-cells\/"},"modified":"2026-08-05T00:46:15","modified_gmt":"2026-08-04T22:46:15","slug":"meditope-enabled-chimeric-antigen-receptors-facilitate-plug-and-play-control-of-t-cells","status":"publish","type":"post","link":"https:\/\/inmuno.es\/index.php\/2026\/08\/05\/meditope-enabled-chimeric-antigen-receptors-facilitate-plug-and-play-control-of-t-cells\/","title":{"rendered":"Meditope-Enabled Chimeric Antigen Receptors Facilitate Plug-and-Play Control of T Cells"},"content":{"rendered":"<div>\n<p><b>Cancer Immunol Res<\/b>. 2026 Aug 4. doi: 10.1158\/2326-6066.CIR-25-1285. Online ahead of print.<\/p>\n<p><b>ABSTRACT<\/b><\/p>\n<p>Chimeric antigen receptor (CAR) T cells have transformed cancer treatment, yet challenges for achieving broader clinical success remain, including overcoming tumor antigen heterogeneity and limited T-cell fitness. To address these challenges and enhance CAR T-cell functionality, we leveraged meditope technology, a lock-and-key platform where Fab regions of antibodies are modified to bind a small cyclic peptide termed meditope (meP). We developed a panel of meditope-enabled Fab-based CARs (meCARs), which showed selective binding to the meP and comparable activity to traditional single-chain variable fragment (scFv)-based CARs. Focusing on HER2-targeted meCARs for evaluating platform utility, we exploited the modularity of the meditope platform to detect meCAR T cells using meP-fused fluorescent agents, promote meCAR T-cell expansion via meP-fused IL-15 cytokine, and broaden tumor antigen targeting through meP-fused antibodies to address tumor heterogeneity. These findings establish the meditope technology as a versatile strategy to augment CAR T-cell functionality and overcome key limitations of current CAR-based therapies.<\/p>\n<p>PMID:<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/42550958\/?utm_source=SimplePie&amp;utm_medium=rss&amp;utm_content=101614637&amp;ff=20260804184615&amp;v=2.20.0.post5+40e1b98\">42550958<\/a> | DOI:<a href=\"https:\/\/doi.org\/10.1158\/2326-6066.CIR-25-1285\">10.1158\/2326-6066.CIR-25-1285<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Cancer Immunol Res. 2026 Aug 4. doi: 10.1158\/2326-6066.CIR-25-1285. Online ahead of print. ABSTRACT Chimeric antigen receptor (CAR) T cells have transformed cancer treatment, yet challenges for achieving broader clinical success remain, including overcoming tumor antigen heterogeneity and limited T-cell fitness. To address these challenges and enhance CAR T-cell functionality, we leveraged meditope technology, a lock-and-key &#8230; <a title=\"Meditope-Enabled Chimeric Antigen Receptors Facilitate Plug-and-Play Control of T Cells\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/08\/05\/meditope-enabled-chimeric-antigen-receptors-facilitate-plug-and-play-control-of-t-cells\/\" aria-label=\"Read more about Meditope-Enabled Chimeric Antigen Receptors Facilitate Plug-and-Play Control of T Cells\">Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[55,42],"tags":[],"class_list":["post-72220","post","type-post","status-publish","format-standard","hentry","category-cancer-immunology-reserch","category-publicaciones"],"_links":{"self":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/72220","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/comments?post=72220"}],"version-history":[{"count":0,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/72220\/revisions"}],"wp:attachment":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/media?parent=72220"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/categories?post=72220"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/tags?post=72220"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}